CSL Limited (CSLLY)
USD 81.65
(0.89%)
USD 81.65
(0.89%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 | 11.23 Billion USD | 1.12% |
| 2023 | 11.17 Billion USD | 116.35% |
| 2022 | 5.16 Billion USD | -3.17% |
| 2021 | 5.33 Billion AUD | -7.9% |
| 2020 | 5.79 Billion AUD | 36.5% |
| 2019 | 4.24 Billion AUD | 1.96% |
| 2018 | 4.16 Billion AUD | 7.99% |
| 2017 | 3.85 Billion AUD | 25.05% |
| 2016 | 3.08 Billion AUD | 35.27% |
| 2015 | 2.27 Billion AUD | 20.85% |
| 2014 | 1.88 Billion AUD | 12.64% |
| 2013 | 1.67 Billion AUD | 48.04% |
| 2012 | 1.13 Billion AUD | 456.5% |
| 2011 | 203.09 Million AUD | -45.22% |
| 2010 | 370.72 Million AUD | 19.19% |
| 2009 | 311.05 Million AUD | -60.6% |
| 2008 | 789.44 Million AUD | 9.42% |
| 2007 | 721.46 Million AUD | 63.35% |
| 2006 | 441.66 Million AUD | -42.25% |
| 2005 | 764.81 Million AUD | 31.04% |
| 2004 | 583.64 Million AUD | 50.0% |
| 2003 | 389.08 Million AUD | 24.47% |
| 2002 | 312.58 Million AUD | 7.88% |
| 2001 | 289.76 Million AUD | 19382.93% |
| 2000 | 1.48 Million AUD | -68.95% |
| 1999 | 4.78 Million AUD | -42.09% |
| 1998 | 8.27 Million AUD | -67.7% |
| 1997 | 25.6 Million AUD | -9.88% |
| 1996 | 28.41 Million AUD | -11.47% |
| 1995 | 32.09 Million AUD | 42.03% |
| 1994 | 22.59 Million AUD | 22913.77% |
| 1993 | 98.19 Thousand AUD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 9.09 Billion USD | 0.0% |
| 2024 Q1 | 16.62 Billion USD | 73.83% |
| 2024 Q4 | 9.67 Billion USD | 0.0% |
| 2024 FY | 11.23 Billion USD | 0.6% |
| 2023 Q2 | 9.57 Billion USD | -43.84% |
| 2023 Q1 | 17.04 Billion USD | 230.1% |
| 2023 FY | 11.17 Billion USD | 116.35% |
| 2023 Q4 | 11.17 Billion USD | -33.15% |
| 2023 Q3 | 16.71 Billion USD | 74.58% |
| 2022 Q4 | 5.16 Billion USD | -25.18% |
| 2022 Q1 | 7.19 Billion USD | 34.85% |
| 2022 Q2 | 4 Billion USD | -44.24% |
| 2022 Q3 | 6.9 Billion USD | 72.13% |
| 2022 FY | 5.16 Billion USD | -3.17% |
| 2021 Q1 | 7.93 Billion USD | -5.96% |
| 2021 Q3 | 7.02 Billion USD | 53.06% |
| 2021 Q4 | 5.33 Billion AUD | -24.04% |
| 2021 FY | 5.33 Billion AUD | -7.9% |
| 2021 Q2 | 4.58 Billion USD | -42.18% |
| 2020 FY | 5.79 Billion AUD | 36.5% |
| 2020 Q3 | 9.41 Billion USD | 157.52% |
| 2020 Q4 | 8.43 Billion AUD | -10.39% |
| 2020 Q1 | 6.93 Billion USD | 63.46% |
| 2020 Q2 | 3.65 Billion USD | -47.27% |
| 2019 FY | 4.24 Billion AUD | 1.96% |
| 2019 Q3 | 5.97 Billion USD | 2.45% |
| 2019 Q1 | 5.68 Billion USD | 36.6% |
| 2019 Q2 | 5.83 Billion USD | 2.61% |
| 2019 Q4 | 4.24 Billion AUD | -29.0% |
| 2018 Q3 | 5.41 Billion USD | 2.46% |
| 2018 FY | 4.16 Billion AUD | 7.99% |
| 2018 Q1 | 5.25 Billion USD | 36.52% |
| 2018 Q2 | 5.28 Billion USD | 0.5% |
| 2018 Q4 | 4.16 Billion AUD | -23.18% |
| 2017 Q2 | 4.86 Billion USD | 6.07% |
| 2017 FY | 3.85 Billion AUD | 25.05% |
| 2017 Q4 | 3.85 Billion AUD | -23.6% |
| 2017 Q3 | 5.04 Billion USD | 3.74% |
| 2017 Q1 | 4.58 Billion USD | 48.74% |
| 2016 Q1 | 4.29 Billion USD | 88.46% |
| 2016 FY | 3.08 Billion AUD | 35.27% |
| 2016 Q3 | 4 Billion USD | -3.26% |
| 2016 Q2 | 4.14 Billion USD | -3.47% |
| 2016 Q4 | 3.08 Billion AUD | -23.14% |
| 2015 Q3 | 2.98 Billion USD | 4.92% |
| 2015 FY | 2.27 Billion AUD | 20.85% |
| 2015 Q1 | 2.66 Billion USD | 41.27% |
| 2015 Q2 | 2.84 Billion USD | 6.9% |
| 2015 Q4 | 2.27 Billion AUD | -23.73% |
| 2014 Q1 | 1.91 Billion USD | 14.16% |
| 2014 Q3 | 2.03 Billion USD | 1.82% |
| 2014 Q2 | 1.99 Billion USD | 4.51% |
| 2014 FY | 1.88 Billion AUD | 12.64% |
| 2014 Q4 | 1.88 Billion AUD | -7.28% |
| 2013 Q1 | 1.08 Billion USD | -4.44% |
| 2013 Q2 | 1.07 Billion USD | -0.06% |
| 2013 Q3 | 1.6 Billion USD | 48.93% |
| 2013 Q4 | 1.67 Billion AUD | 4.09% |
| 2013 FY | 1.67 Billion AUD | 48.04% |
| 2012 Q4 | 1.13 Billion AUD | 0.0% |
| 2012 FY | 1.13 Billion AUD | 456.5% |
| 2011 Q4 | 203.09 Million AUD | 0.0% |
| 2011 FY | 203.09 Million AUD | -45.22% |
| 2010 FY | 370.72 Million AUD | 19.19% |
| 2010 Q4 | 370.72 Million AUD | 0.0% |
| 2009 Q4 | 311.05 Million AUD | 0.0% |
| 2009 FY | 311.05 Million AUD | -60.6% |
| 2008 Q4 | 789.44 Million AUD | 0.0% |
| 2008 FY | 789.44 Million AUD | 9.42% |
| 2007 Q4 | 721.46 Million AUD | 0.0% |
| 2007 FY | 721.46 Million AUD | 63.35% |
| 2006 FY | 441.66 Million AUD | -42.25% |
| 2006 Q4 | 441.66 Million AUD | 0.0% |
| 2005 FY | 764.81 Million AUD | 31.04% |
| 2005 Q4 | 764.81 Million AUD | 0.0% |
| 2004 Q4 | 583.64 Million AUD | 0.0% |
| 2004 FY | 583.64 Million AUD | 50.0% |
| 2003 Q4 | 389.08 Million AUD | 0.0% |
| 2003 FY | 389.08 Million AUD | 24.47% |
| 2002 FY | 312.58 Million AUD | 7.88% |
| 2002 Q4 | 312.58 Million AUD | 0.0% |
| 2001 Q4 | 289.76 Million AUD | 0.0% |
| 2001 FY | 289.76 Million AUD | 19382.93% |
| 2000 Q4 | 1.48 Million AUD | 0.0% |
| 2000 FY | 1.48 Million AUD | -68.95% |
| 1999 Q4 | 4.78 Million AUD | 0.0% |
| 1999 FY | 4.78 Million AUD | -42.09% |
| 1998 Q4 | 8.27 Million AUD | 0.0% |
| 1998 FY | 8.27 Million AUD | -67.7% |
| 1997 Q4 | 25.6 Million AUD | 0.0% |
| 1997 FY | 25.6 Million AUD | -9.88% |
| 1996 FY | 28.41 Million AUD | -11.47% |
| 1995 FY | 32.09 Million AUD | 42.03% |
| 1994 FY | 22.59 Million AUD | 22913.77% |
| 1993 FY | 98.19 Thousand AUD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | - USD | -Infinity% |
| Evofem Biosciences, Inc. | 8000.00 USD | -140487400.0% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 1.75 Million USD | -640124.121% |
| Qrons Inc. | 80 Thousand USD | -14048650.0% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 20.31 Million USD | -55231.824% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Skye Bioscience, Inc. | 171.23 Thousand USD | -6563586.27% |
| Eiger BioPharmaceuticals, Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 20.9 Million USD | -53651.973% |
| Intellipharmaceutics International Inc. | - USD | -Infinity% |
| Propanc Biopharma, Inc. | 58.64 Thousand USD | -19165344.562% |
| Mesoblast Limited | 100.29 Million USD | -11105.951% |
| Marizyme, Inc. | 667.12 Thousand USD | -1684581.673% |
| Genus plc | 228.2 Million USD | -4825.066% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 166.1 Million USD | -6666.202% |
| Therapeutic Solutions International, Inc. | 5512.00 USD | -203900480.552% |
| CNBX Pharmaceuticals Inc. | - USD | -Infinity% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | 2.21 Million USD | -508452.036% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.4 Million USD | -801006.823% |
| IMV Inc. | 27.39 Million USD | -40920.386% |
| AXIM Biotechnologies, Inc. | 5.42 Million USD | -207014.004% |
| MultiCell Technologies, Inc. | 36.43 USD | -30850946921.685% |
| ONE Bio Corp. | 592.19 Thousand USD | -1897744.978% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 55.61 Million USD | -20109.667% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 2.22 Million USD | -504796.676% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -914859.039% |
| Biomind Labs Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 554.59 Thousand USD | -2026442.13% |
| Provectus Biopharmaceuticals, Inc. | 25.29 Thousand USD | -44424580.817% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 1.89 Million USD | -591903.658% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | 322 Thousand USD | -3490272.671% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 150 Thousand USD | -7492566.667% |
| Enzolytics Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 164.2 Thousand USD | -6844393.164% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 15.35 Million USD | -73099.166% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 4456.00 USD | -252221623.519% |
| Genscript Biotech Corporation | 287.12 Million USD | -3814.268% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 126.3 Thousand USD | -8898413.088% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -4901531.551% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 229.69 Thousand USD | -4892995.507% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 8.26 Million USD | -135899.516% |
| BioStem Technologies, Inc. | 265.63 Thousand USD | -4230893.657% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 1064.00 USD | -1056296892.481% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -7511897.54% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -7511897.54% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | 141 Thousand USD | -7970821.986% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -143621.963% |
| SYBLEU INC | 300 Thousand USD | -3746233.333% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 369.04 Thousand USD | -3045295.056% |
| International Stem Cell Corporation | 445 Thousand USD | -2525517.978% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.15 Million USD | -137801.84% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | 457 Thousand USD | -2459199.781% |
| Neutra Corp. | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | 1.16 Million USD | -967944.789% |
| PureTech Health plc | 18.25 Million USD | -61483.562% |
| Coeptis Therapeutics, Inc. | 150 Thousand USD | -7492566.667% |
| IXICO plc | 275 Thousand USD | -4086809.091% |
| IntelGenx Technologies Corp. | 11.83 Million USD | -94832.004% |
| Gelesis Holdings, Inc. | 26.3 Million USD | -42619.222% |
| CSL Limited | 11.23 Billion USD | 0.0% |
| Cellectis S.A. | 36.21 Million USD | -30937.406% |